Brind.

Novo Nordisk became the licensee for Lexicon's LX9851, and Viatris filed to bring sotagliflozin to markets.

2 reports, 2 independent Updated Aug 6

Gone quiet Reached 2 outlets in its first 24 hours

Reports: 2
Developments: 2
Repetition: 0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Novo Nordisk became the licensee for Lexicon's LX9851, and Viatris filed to bring sotagliflozin to markets.

Who's involved

What this event is mainly about

Lexicon Pharmaceuticals Novo Nordisk Mylan

How it developed

Newest first. Tap a step to see who reported it.

Aug 6Novo Nordisk licenses Lexicon's LX9851; Viatris files sotagliflozin.1 source
- GlobeNewswire
Jul 20Sotagliflozin showed a promising clinical profile for Type 1 Diabetes.1 source
- Insider Monkey

Keep exploring

The entities involved

Lexicon Pharmaceuticals
biopharmaceutical company

Nothing else this week.
Novo Nordisk
Danish pharmaceutical company
- Eli Lilly and Company received full FDA approval, expanded a safety study into India, and broke ground on a new facility in Houston while competing in the GLP-1 market.Fri 19:45
- Eli Lilly's tirzepatide proved more effective than Novo Nordisk's semaglutide in the obesity drug market.Thu 17:25
Mylan
former pharmaceutical company

Nothing else this week.

Coverage

Newest first; wire copies grouped

Aug 6GlobeNewswireLexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates Partnership discussions for pilavapadin remain underway following Phase 2b PROGRESS study results I
Jul 20Insider MonkeyH.C. Wainwright Reiterates a Buy Rating on Lexicon Pharmaceuticals (LXRX) Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is one of the hot penny stocks to invest in now. H.C. Wainwright analyst Joseph P